• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Anteris Technologies Global Corp. filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits

    9/11/25 9:07:34 AM ET
    $AVR
    Industrial Specialties
    Health Care
    Get the next $AVR alert in real time by email
    false000201151400020115142025-09-112025-09-11

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    FORM 8-K



    CURRENT REPORT
    Pursuant to Section 13 OR 15(d)
    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): September 11, 2025



    Anteris Technologies Global Corp.
    (Exact name of registrant as specified in its charter)



    Delaware
    001-42437
    99-1407174
    (State or Other Jurisdiction of Incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification No.)

    Toowong Tower, Level 3, Suite 302
    9 Sherwood Road
    Toowong, QLD
    Australia
     
    4066
    (Address of Principal Executive Offices)
     
    (Zip Code)

    Registrant’s telephone number, including area code: +61 7 3152 3200

    Not Applicable
    (Former name or former address, if changed since last report)



    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading
    Symbol(s)
     
    Name of each exchange
    on which registered
    Common Stock, par value $0.0001 per share
     
    AVR
     
    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 8.01.
    Other Events.
     
    On September 11, 2025, Anteris Technologies Global Corp. (the “Company”) issued a press release announcing the postponement of the Company’s Special Meeting of Stockholders until Thursday, September 18, 2025, at 5:00 p.m. Central time (being 8:00 a.m. AEST on Friday, September 19, 2025). A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.

    Item 9.01.
    Financial Statements and Exhibits.

    (d)
    Exhibits.

    The following exhibit is filed with this Current Report on Form 8-K:

    Exhibit
    No.
     
    Description
    99.1
     
    Press Release, dated September 11, 2025
         
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     
    Anteris Technologies Global Corp.
       
    Date: September 11, 2025
       
         
     
    By:
    /s/ Wayne Paterson
     
    Name:
    Wayne Paterson
     
    Title:
    Vice Chairman and Chief Executive Officer



    Get the next $AVR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVR

    DatePrice TargetRatingAnalyst
    1/8/2025$20.00Buy
    Lake Street
    1/7/2025$15.00Buy
    TD Cowen
    1/7/2025$9.00Overweight
    Cantor Fitzgerald
    1/7/2025$22.00Overweight
    Barclays
    More analyst ratings

    $AVR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the "PARADIGM Trial")

    MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the first patients have been enrolled and successfully treated in the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the "PARADIGM Trial"). The procedures were performed by Prof. Dr. Ole De Backer at, The Heart Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. "We a

    10/27/25 5:43:37 PM ET
    $AVR
    Industrial Specialties
    Health Care

    Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025

    MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)), a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced that one-year clinical outcomes with the DurAVR® Transcatheter Heart Valve (THV) will be presented by Rishi Puri MD PhD, at TCT® 2025 – The 37th Annual Transcatheter Cardiovascular Therapeutics® Conference, taking place in San Francisco, California, October 25-28, 2025. An oral presentation is scheduled for Monday, October 27 (2:27pm GMT-7) in the Innovation Theater, Ha

    10/27/25 8:43:48 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the "PARADIGM Trial")

    MINNEAPOLIS and BRISBANE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has received regulatory clearance from the Danish Medicines Agency to initiate the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial in patients with severe calcific aortic stenosis (the "PARADIGM Trial"). Patient recruitment at Danish centers is expected to begin in 4Q 2025. PARADIGM: A Prospective rAndomized tRial Assessing the safety and effectiveness of

    10/15/25 9:18:14 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Moss Gregory S.

    3 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    6/10/25 6:01:58 AM ET
    $AVR
    Industrial Specialties
    Health Care

    SEC Form 3 filed by new insider Roberts David B

    3 - Anteris Technologies Global Corp. (0002011514) (Issuer)

    6/10/25 6:01:52 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Amendment: Director Seaberg John D exercised 40,000 shares at a strike of $7.13 and covered exercise/tax liability with 36,148 shares (SEC Form 4)

    4/A - Anteris Technologies Global Corp. (0002011514) (Issuer)

    3/21/25 9:30:47 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Anteris Technologies Global Corp. with a new price target

    Lake Street initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $20.00

    1/8/25 8:52:46 AM ET
    $AVR
    Industrial Specialties
    Health Care

    TD Cowen initiated coverage on Anteris Technologies Global Corp. with a new price target

    TD Cowen initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $15.00

    1/7/25 9:02:46 AM ET
    $AVR
    Industrial Specialties
    Health Care

    Cantor Fitzgerald initiated coverage on Anteris Technologies Global Corp. with a new price target

    Cantor Fitzgerald initiated coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $9.00

    1/7/25 9:00:55 AM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    SEC Filings

    View All

    Anteris Technologies Global Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Anteris Technologies Global Corp. (0002011514) (Filer)

    10/27/25 9:11:18 PM ET
    $AVR
    Industrial Specialties
    Health Care

    Anteris Technologies Global Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events

    8-K - Anteris Technologies Global Corp. (0002011514) (Filer)

    10/27/25 5:26:57 PM ET
    $AVR
    Industrial Specialties
    Health Care

    Anteris Technologies Global Corp. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Anteris Technologies Global Corp. (0002011514) (Filer)

    10/24/25 5:10:36 PM ET
    $AVR
    Industrial Specialties
    Health Care

    $AVR
    Leadership Updates

    Live Leadership Updates

    View All

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments